You are here: Industry Insights > Novavax

News List

Novavax and SK bioscience Expand Manufacturing Agreement prnasia
December 24, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience...
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies prnasia
December 23, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial data evaluating the immune response of its COVID-19 vaccine...
World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine prnasia
December 22, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization...
Novavax gets EC marketing authorization for Covid-19 vaccine By PBR Staff Writer Pharmaceutical-Business-Review
December 22, 2021
Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial SARS-CoV-2 virus strain.
World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine prnasia
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO)...
European Commission grants conditional marketing authorization for Novavax COVID-19 vaccine WorldPharmaNews
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC)...
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine prnewswire
December 21, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA)...
Novavax and SII obtain WHO Emergency Use Listing for Covid-19 vaccine Pharmaceutical-Technology
December 21, 2021
Novavax and its partner Serum Institute of India (SII) have obtained Emergency Use Listing (EUL) from the World Health Organization (WHO) for the former’s recombinant nanoparticle protein-based Covid-19 vaccine with Matrix-M adjuvant, NVX-CoV2373.
Novavax’s COVID-19 vaccine highly effective in preventing disease EuropeanPharmaceuticalReview
December 20, 2021
Recently published data suggests Novavax’s investigational COVID-19 vaccine, NVX-CoV2373, is 90 percent effective at preventing COVID-19 illness and 100 percent effective at preventing moderate-to-severe symptoms.
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine prnasia
December 17, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the submission of a New Drug Application (NDA)...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page